Trial reportPsychopharmacology2004
Amisulpride is an "atypical" antipsychotic associated with low weight gain.
Trial report in Psychopharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 41 citations in OpenAlex.
- Genetic association of the rs17782313 polymorphism with antipsychotic-induced weight gain.Psychopharmacology · 2023Trial
- A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia.Clinical drug investigation · 2012Trial
- The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study.BMC psychiatry · 2005Trial
- Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses.Clinical pharmacokinetics · 2020Article
- The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study.Neuropsychiatric disease and treatment · 2017Article
- Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride.Journal of clinical and diagnostic research : JCDR · 2015Article
- Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients.Journal of pharmacology & pharmacotherapeutics · 2013Article
- Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study.Therapeutic advances in psychopharmacology · 2011Article
- Safety and tolerability of antipsychotics: focus on amisulpride.Drug, healthcare and patient safety · 2010Article
- [Atypical antipsychotics and metabolic syndrome].Wiener medizinische Wochenschrift (1946) · 2007Review
- Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis.Drug safety · 2006Review
- Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.CNS drugs · 2005Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleIt is possible that amisulpride, with its unique receptor binding profile, is not associated with significant weight gain, a serious side effect of most "atypical" antipsychotic drugs. While most "atypicals" have a high affinity for both dopamine and serotonin receptors, amisulpride has only dopamine receptor action.
objectivesTo analyse the weight gain associated with amisulpride.
methodsA pooled database of prospective randomised amisulpride studies was analysed. The mean weight gain after 10 weeks of treatment was estimated by regression analysis.
resultsEleven studies with a total of 1422 patients were pooled, providing 1392 patients who were eligible for evaluation. In the main analysis of all effective doses (50-1200 mg/day) the mean weight gain associated with amisulpride at 10 weeks was 0.8 kg, 95% CI (0.48-1.18). Linear regression showed no dependence of weight gain on daily dose levels (P=0.7). When patients with mean daily doses below 400 mg/day were excluded in a sensitivity analysis, the mean weight gain at ten weeks was again 0.80 kg, 95% CI (0.47-1.16) with n=874. The mean weight gain at study endpoints in 1-year studies was 1.4 kg, 95% CI (0.85-1.90), n=548.
conclusionAmisulpride is an atypical antipsychotic associated with low weight gain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.